| Metric | Value ($ M) | Q1 FY25 |
|---|---|---|
| Revenue | 9.13 | 22.0% |
| Total Income | 9.13 | 22.0% |
| Expenditure | 12.26 | 17.7% |
| PBT | -3.14 | 351.2% |
| Net Profit | -3.29 | 361.1% |
| OPM | -34.27% | 45.30pp |
| NPM | -36.03% | 46.76pp |
| EPS | -0.22 | 375.0% |
Cumberland Pharmaceuticals Reports Q1 2026 Net Revenues of $9.1 Million
06 May 2026 · 6 May, 2:42 am
Summary
Cumberland Pharmaceuticals Inc. announced its Q1 2026 financial results, reporting net revenues of $9.1 million, a 5% increase compared to Q1 2025 when excluding a milestone payment. The company reported a net loss of $3.3 million for the quarter, with an adjusted loss of $1.9 million, or $0.13 per share. Cumberland also announced a strategic transaction with Apotex Inc. expected to unlock $100 million in value. The company is sharpening its focus on developing high-value product candidates.
Key Highlights
- 1
Cumberland Pharmaceuticals reported net revenues of $9.1 million for the first quarter of 2026.
- 2
This represents a 5% increase compared to the first quarter of 2025, after removing a $3 million milestone payment.
- 3
The company ended the quarter with $71.0 million in total assets.
- 4
The net loss for the first quarter of 2026 was approximately $3.3 million.
- 5
Adjusted loss for the quarter was $1.9 million, or $0.13 per share.
- 6
A strategic transaction with Apotex Inc. will unlock $100 million in value for Cumberland.
Management Comments
A.J. Kazimi
“We entered 2026 with strong momentum following an outstanding 2025, which featured double-digit revenue growth, the addition of a new product to our portfolio, new international approvals and breakthrough clinical study results.” “We have built on that momentum through our recently announced Strategic Transaction, which represents an important next step in our Company’s evolution, enabling us to sharpen our focus on developing high-value product candidates, while unlocking significant value for our shareholders.”
Informational and educational content only. Not investment advice.